The rise and fall of aspirin in the primary prevention of cardiovascular disease

Inbar Raber, Cian P. McCarthy, Muthiah Vaduganathan, Deepak L. Bhatt, David A. Wood, John G.F. Cleland, Roger S Blumenthal, John W. McEvoy

Research output: Contribution to journalReview article

Abstract

Aspirin is one of the most frequently used drugs worldwide and is generally considered effective for the secondary prevention of cardiovascular disease. By contrast, the role of aspirin in primary prevention of cardiovascular disease is controversial. Early trials evaluating aspirin for primary prevention, done before the turn of the millennium, suggested reductions in myocardial infarction and stroke (although not mortality), and an increased risk of bleeding. In an effort to balance the risks and benefits of aspirin, international guidelines on primary prevention of cardiovascular disease have typically recommended aspirin only when a substantial 10-year risk of cardiovascular events exists. However, in 2018, three large randomised clinical trials of aspirin for the primary prevention of cardiovascular disease showed little or no benefit and have even suggested net harm. In this narrative Review, we reappraise the role of aspirin in primary prevention of cardiovascular disease, contextualising data from historical and contemporary trials.

Original languageEnglish (US)
Pages (from-to)2155-2167
Number of pages13
JournalThe Lancet
Volume393
Issue number10186
DOIs
StatePublished - May 25 2019

Fingerprint

Primary Prevention
Aspirin
Cardiovascular Diseases
Secondary Prevention
Randomized Controlled Trials
Stroke
Myocardial Infarction
Guidelines
Hemorrhage
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Raber, I., McCarthy, C. P., Vaduganathan, M., Bhatt, D. L., Wood, D. A., Cleland, J. G. F., ... McEvoy, J. W. (2019). The rise and fall of aspirin in the primary prevention of cardiovascular disease. The Lancet, 393(10186), 2155-2167. https://doi.org/10.1016/S0140-6736(19)30541-0

The rise and fall of aspirin in the primary prevention of cardiovascular disease. / Raber, Inbar; McCarthy, Cian P.; Vaduganathan, Muthiah; Bhatt, Deepak L.; Wood, David A.; Cleland, John G.F.; Blumenthal, Roger S; McEvoy, John W.

In: The Lancet, Vol. 393, No. 10186, 25.05.2019, p. 2155-2167.

Research output: Contribution to journalReview article

Raber, I, McCarthy, CP, Vaduganathan, M, Bhatt, DL, Wood, DA, Cleland, JGF, Blumenthal, RS & McEvoy, JW 2019, 'The rise and fall of aspirin in the primary prevention of cardiovascular disease', The Lancet, vol. 393, no. 10186, pp. 2155-2167. https://doi.org/10.1016/S0140-6736(19)30541-0
Raber I, McCarthy CP, Vaduganathan M, Bhatt DL, Wood DA, Cleland JGF et al. The rise and fall of aspirin in the primary prevention of cardiovascular disease. The Lancet. 2019 May 25;393(10186):2155-2167. https://doi.org/10.1016/S0140-6736(19)30541-0
Raber, Inbar ; McCarthy, Cian P. ; Vaduganathan, Muthiah ; Bhatt, Deepak L. ; Wood, David A. ; Cleland, John G.F. ; Blumenthal, Roger S ; McEvoy, John W. / The rise and fall of aspirin in the primary prevention of cardiovascular disease. In: The Lancet. 2019 ; Vol. 393, No. 10186. pp. 2155-2167.
@article{392387d2c645441d9ca56fae336e5dbd,
title = "The rise and fall of aspirin in the primary prevention of cardiovascular disease",
abstract = "Aspirin is one of the most frequently used drugs worldwide and is generally considered effective for the secondary prevention of cardiovascular disease. By contrast, the role of aspirin in primary prevention of cardiovascular disease is controversial. Early trials evaluating aspirin for primary prevention, done before the turn of the millennium, suggested reductions in myocardial infarction and stroke (although not mortality), and an increased risk of bleeding. In an effort to balance the risks and benefits of aspirin, international guidelines on primary prevention of cardiovascular disease have typically recommended aspirin only when a substantial 10-year risk of cardiovascular events exists. However, in 2018, three large randomised clinical trials of aspirin for the primary prevention of cardiovascular disease showed little or no benefit and have even suggested net harm. In this narrative Review, we reappraise the role of aspirin in primary prevention of cardiovascular disease, contextualising data from historical and contemporary trials.",
author = "Inbar Raber and McCarthy, {Cian P.} and Muthiah Vaduganathan and Bhatt, {Deepak L.} and Wood, {David A.} and Cleland, {John G.F.} and Blumenthal, {Roger S} and McEvoy, {John W.}",
year = "2019",
month = "5",
day = "25",
doi = "10.1016/S0140-6736(19)30541-0",
language = "English (US)",
volume = "393",
pages = "2155--2167",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "10186",

}

TY - JOUR

T1 - The rise and fall of aspirin in the primary prevention of cardiovascular disease

AU - Raber, Inbar

AU - McCarthy, Cian P.

AU - Vaduganathan, Muthiah

AU - Bhatt, Deepak L.

AU - Wood, David A.

AU - Cleland, John G.F.

AU - Blumenthal, Roger S

AU - McEvoy, John W.

PY - 2019/5/25

Y1 - 2019/5/25

N2 - Aspirin is one of the most frequently used drugs worldwide and is generally considered effective for the secondary prevention of cardiovascular disease. By contrast, the role of aspirin in primary prevention of cardiovascular disease is controversial. Early trials evaluating aspirin for primary prevention, done before the turn of the millennium, suggested reductions in myocardial infarction and stroke (although not mortality), and an increased risk of bleeding. In an effort to balance the risks and benefits of aspirin, international guidelines on primary prevention of cardiovascular disease have typically recommended aspirin only when a substantial 10-year risk of cardiovascular events exists. However, in 2018, three large randomised clinical trials of aspirin for the primary prevention of cardiovascular disease showed little or no benefit and have even suggested net harm. In this narrative Review, we reappraise the role of aspirin in primary prevention of cardiovascular disease, contextualising data from historical and contemporary trials.

AB - Aspirin is one of the most frequently used drugs worldwide and is generally considered effective for the secondary prevention of cardiovascular disease. By contrast, the role of aspirin in primary prevention of cardiovascular disease is controversial. Early trials evaluating aspirin for primary prevention, done before the turn of the millennium, suggested reductions in myocardial infarction and stroke (although not mortality), and an increased risk of bleeding. In an effort to balance the risks and benefits of aspirin, international guidelines on primary prevention of cardiovascular disease have typically recommended aspirin only when a substantial 10-year risk of cardiovascular events exists. However, in 2018, three large randomised clinical trials of aspirin for the primary prevention of cardiovascular disease showed little or no benefit and have even suggested net harm. In this narrative Review, we reappraise the role of aspirin in primary prevention of cardiovascular disease, contextualising data from historical and contemporary trials.

UR - http://www.scopus.com/inward/record.url?scp=85065983838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065983838&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(19)30541-0

DO - 10.1016/S0140-6736(19)30541-0

M3 - Review article

C2 - 31226053

AN - SCOPUS:85065983838

VL - 393

SP - 2155

EP - 2167

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10186

ER -